2017
BOTHELL, Washington, 14 December 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how...
Bothell, WA, 13 December 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how...
London, UK, 11 December 2017 Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres BTG...
27 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board. Greg has a broad range...
16 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, announces the publication of new consensus guidelines for use of Voraxaze® (glucarpidase) in patients with high-dose...
London, UK, 14 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today announces its interim results for the six months ended 30 September 2017. Click here to download...
London, UK, 14 November 2017 BTG plc: Directorate change – Chief Financial Officer BTG plc (LSE: BTG), the global specialist healthcare company, announces that after 10 years as Chief Financial...
London, UK, 06 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, announces that the Court of Chancery of Delaware has issued its final order and judgement in relation to...
London, UK, 06 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, notes that the US Centers for Medicare and Medicaid Services have published the final fee schedule for...
London, UK, 09 October 2017 Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc (LSE: BTG) have begun the first clinical trial of an experimental treatment for...